Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IVIG or intralipid for elevated NK cell activity in recurrent pregnancy loss or implantation failure
jRCTs021180020Completed
- Start
- Apr 2015
- Modality
- Recombinant Proteins and Enzymes, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Open-label trial of immune globulin and Intralipid 10% in recurrent miscarriage (RPL), Recurrent Implantation Failure (RIF) and None (2 arms). Primary endpoints: pregnancy rate and live birth rate. Started Apr 2015; status: completed.
02
Drugs
immune globulinIntralipid 10%
03
Conditions
recurrent miscarriage (RPL)Recurrent Implantation Failure (RIF)
Beyond the preview
Go deeper on jRCTs021180020.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs021180020.